ArticleJournal of diabetes and metabolic disorders2025
Predictive value of the Triglyceride-Glucose index in diabetic macular edema: A comparative analysis with HbA1c.
Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the correlation between the Triglyceride-Glucose index (TyG) and the presence of diabetic macular edema (DME), is a microvascular consequence of diabetes, and to examine its predictive power in comparison with hemoglobin A1c test (HbA1c). Materials and methods: A total of 101 patients were enrolled in the research study. The study participants were divided into three groups: patients with DME ( Results: The highest TyG index values were seen in the DME patient group, and a significant difference was noted between this group and the others (8.5 ± 0.59; Conclusion: The TyG index is an important indicator of microvascular complications and metabolic stress. When used alongside HbA1c, the TyG index has been shown to provide clinical benefits as a complementary biomarker for assessing metabolic control in patients with DME. Therefore, managing TyG values alongside HbA1c is recommended as a secondary treatment target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.